

| | | | |
|--|--|---------------------------------|----------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small> | | Complete if Known | |
| | | Application Number | 10/048,072 |
| | | Filing Date | January 25, 2002 |
| | | First Named Inventor | Franchini, Genoveffa |
| | | Group Art Unit | 1648 |
| | | Examiner Name | Parkin, Jeffrey |
| Sheet 1 of 1 | | Attorney Docket No: 1662.018US1 | |

| OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS | | | |
|---|----------------------|--|---|
| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
| | | BELSHE, R. , et al., "Support for the RV144 HIV vaccine trial.", <u>Science</u> , 305(5681), (July 9, 2004), 177-80 | |
| | | CORREA, R. , et al., "Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure", <u>AIDS</u> , 21(1), (2007), 23-30 | |
| | | GOMEZ, C. E., et al., "Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C", <u>Vaccine</u> , 25(11), (2007), 1969-92 | |
| | | GOMEZ, C. E., et al., "Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B", <u>Vaccine</u> , In Press, Corrected Proof, Available online 16 October 2006, (2006), | |
| | | JACOBSON, J. M., et al., "Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068", <u>J Infect Dis.</u> , 194(5), (2006), 623-32 | |
| | | JEFFERYS, R. , et al., "Outstanding questions on HIV vaccine trial", <u>Science</u> , 305(5681), (July 9, 2004), 180 | |
| | | JILEK, S. , et al., "CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis", <u>Clinical Immunology</u> , 123(1), (2007), 105-113 | |
| | | KILBY, J. , et al., "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).", <u>The Journal of Infectious Diseases</u> , 194(12), (2006), 1672-6 | |
| | | PAL, R. , et al., "Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.", <u>J Virol.</u> , 80(8), (Apr., 2006), 3732-42 | |
| | | PETERS, BARRY S., et al., "Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity", <u>Vaccine</u> , 25(11), (2007), 2120-2127 | |
| | | TRINVUTHIPONG, C. , "Thailand's Prime-Boost HIV Vaccine Phase III", <u>Science</u> , 303(5660), (Feb. 13, 2004), 954-5 | |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

* IDS fails to comply with 37 CFR 1.97(d).